IKBKE and asthma: Amlexanox, an FDA-approved TBK1/IKKε inhibitor initially designed to treat asthma and dental ulcers, has now been found to be valuable for ameliorating inflammatory response in some diseases, including autoimmune encephalitis and sporadic aortic aneurysm and dissection (AAD), making it a candidate for clinical use in targeting the cytosolic DNA sensor-STING pathway (Luo et al, 2020; Quan et al, 2019).